Detalhe da pesquisa
1.
BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.
Acta Haematol
; 134(4): 248-54, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26159458
2.
Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
Clinics (Sao Paulo)
; 70(8): 550-5, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26247667
3.
Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience
Clinics
; 70(8): 550-555, 08/2015. tab, graf
Artigo
em Inglês
| LILACS | ID: lil-753967